Publicaciones (264) Publicaciones de ATANASIO PANDIELLA ALONSO

2024

  1. ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 6

2023

  1. An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer

    Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200

  2. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs

    Cancer Letters, Vol. 554

  3. Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer

    International Journal of Biological Sciences, Vol. 19, Núm. 6, pp. 1731-1747

  4. Considerations for the clinical development of immuno-oncology agents in cancer

    Frontiers in immunology, Vol. 14, pp. 1229575

  5. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

  3. Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers

    Cancers, Vol. 14, Núm. 18

  4. Genomic mapping of copy number variations influencing immune response in breast cancer

    Frontiers in Oncology, Vol. 12

  5. HER3 in cancer: from the bench to the bedside

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  6. Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

    Biomolecules, Vol. 12, Núm. 11

  7. Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21

    Cancer Research, Vol. 82, Núm. 3, pp. 447-457

  8. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

  9. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

  10. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  11. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

  12. Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates

    Frontiers in Immunology, Vol. 12

  13. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer

    Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121

2021

  1. Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1